CurveBeam AI (ASX:CVB) does not expect any material impact from the Trump administration's tariffs, saying most of the components it uses come from US partners, according to a Tuesday filing with the Australian bourse.
The company, which makes point-of-care specialized medical imaging equipment, conducts its manufacturing activities within the US. The majority of components derived from its US partners represent around 75% of the cost of goods, per the filing.
"Based on an initial risk assessment, the company does not expect material adverse effects from the tariff changes," CurveBeam said in the filing.
The company's shares were up 6% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.